NCT02661542: Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas

NCT02661542
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated unstable brain metastasis- see trial for details
https://ClinicalTrials.gov/show/NCT02661542

Comments are closed.

Up ↑